Physician frontline treatment preferences for stage III/IV classic Hodgkin lymphoma : the real-world US CONNECT study
Aim: To understand US physicians' frontline (1L) treatment preferences/decision-making for stage III/IV classic Hodgkin lymphoma (cHL). Materials & methods: Medical oncologists and/or hematologists (≥2 years' practice experience) who treat adults with stage III/IV cHL were surveyed online (October-November 2020). Results: Participants (n = 301) most commonly considered trial efficacy/safety data and national guidelines when selecting 1L cHL treatments. Most physicians (91%) rated overall survival (OS) as the most essential attribute when selecting 1L treatment. Variability was seen among regimen selection for hypothetical newly diagnosed patients, with OS cited as the most common reason for regimen selection. Conclusion: While treatment selection varied based on patient characteristics, US physicians consistently cited OS as the top factor considered when selecting a 1L treatment for cHL.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Future oncology (London, England) - 20(2024), 12 vom: 25. Apr., Seite 749-760 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Evens, Andrew M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Brentuximab vedotin |
|---|
| Anmerkungen: |
Date Completed 26.03.2024 Date Revised 10.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/fon-2023-0358 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361629885 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361629885 | ||
| 003 | DE-627 | ||
| 005 | 20240410232214.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fon-2023-0358 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM361629885 | ||
| 035 | |a (NLM)37665273 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Evens, Andrew M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Physician frontline treatment preferences for stage III/IV classic Hodgkin lymphoma |b the real-world US CONNECT study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.03.2024 | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: To understand US physicians' frontline (1L) treatment preferences/decision-making for stage III/IV classic Hodgkin lymphoma (cHL). Materials & methods: Medical oncologists and/or hematologists (≥2 years' practice experience) who treat adults with stage III/IV cHL were surveyed online (October-November 2020). Results: Participants (n = 301) most commonly considered trial efficacy/safety data and national guidelines when selecting 1L cHL treatments. Most physicians (91%) rated overall survival (OS) as the most essential attribute when selecting 1L treatment. Variability was seen among regimen selection for hypothetical newly diagnosed patients, with OS cited as the most common reason for regimen selection. Conclusion: While treatment selection varied based on patient characteristics, US physicians consistently cited OS as the top factor considered when selecting a 1L treatment for cHL | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a brentuximab vedotin | |
| 650 | 4 | |a classic Hodgkin lymphoma | |
| 650 | 4 | |a frontline | |
| 650 | 4 | |a patient characteristics | |
| 650 | 4 | |a physician survey | |
| 650 | 4 | |a treatment decision-making | |
| 700 | 1 | |a Yu, Kristina S |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Nicholas |e verfasserin |4 aut | |
| 700 | 1 | |a Surinach, Andy |e verfasserin |4 aut | |
| 700 | 1 | |a Holmes, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Flores, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Fanale, Michelle A |e verfasserin |4 aut | |
| 700 | 1 | |a Flora, Darcy R |e verfasserin |4 aut | |
| 700 | 1 | |a Parsons, Susan K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future oncology (London, England) |d 2005 |g 20(2024), 12 vom: 25. Apr., Seite 749-760 |w (DE-627)NLM161450725 |x 1744-8301 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2024 |g number:12 |g day:25 |g month:04 |g pages:749-760 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/fon-2023-0358 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2024 |e 12 |b 25 |c 04 |h 749-760 | ||